<DOC>
	<DOCNO>NCT00635726</DOCNO>
	<brief_summary>This phase II trial study effectiveness toxicity sequential high dose MVAC follow gemcitabine cisplatin , first line treatment patient locally advance metastatic bladder cancer .</brief_summary>
	<brief_title>Methotrexate , Vinblastine , Doxorubicin Cisplatin ( MVAC ) Followed Gemcitabine Plus Cisplatin ( GEM+CDDP ) Locally Advanced Metastatic Bladder Cancer</brief_title>
	<detailed_description>High dose MVAC Cisplatin/Gemcitabine combination regimen show comparable efficacy first line treatment advance metastatic bladder cancer , whereas latter regimen well tolerability . The efficacy tolerability sequential administration two regimen know .</detailed_description>
	<mesh_term>Urinary Bladder Neoplasms</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Vinblastine</mesh_term>
	<criteria>Histologically cytologically confirm transitional cell carcinoma urinary bladder . Metastatic locally advance disease . No prior chemotherapy . Performance status ( World Health Organization ) 02 . Measurable evaluable disease . Measurable disease define least 1 unidimensional measurable lesion ≥20 mm conventional technique 1 bidimensionally measurable lesion ≥ 20 X 10 mm . Lesions small uni bidimensionally unmeasurable consider evaluable disease . Adequate liver ( bilirubin ≤ 1.5 Upper Normal Limit , serum glutamatepyruvate aminotransferase/serum glutamic pyruvic transaminase ≤ 2 Upper Normal Limit , ALP ≤ 2.5 Upper Normal Limit ) , renal ( creatinine ≤ 1.5 Upper Normal Limit ) bone marrow ( absolute neutrophil count ≥ 1,500/mm3 , platelet count ≥ 100,000/mm3 ) function . Life expectancy &gt; 3 month . Patients must able understand nature study give write informed consent . History serious cardiac disease ( unstable angina , severe congestive heart failure , myocardial infarction within previous 6 month , ventricular arrhythmia ) . Second primary malignancy , except nonmelanoma skin cancer situ cervical cancer . Active infection . Uncontrolled inflammation . Pregnant lactating woman . Psychiatric illness social situation would preclude study compliance .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>October 2015</verification_date>
	<keyword>Bladder Cancer</keyword>
</DOC>